MAGEA3 and sarcoma: HLA-A mRNA expression and HLA-DPB1 mRNA expression were found to be significantly higher in UPS/MFS compared to other sarcomas, suggesting that efficacy of TCR-based immunotherapies targeting MAGEA3 may not be limited by loss of HLA expression.